Executive Function and Contingency Management in Methamphetamine Use Disorder

Lara J van Nunen1,*, Marilyn T Lake1,2, Jonathan C Ipser1, Dan J Stein3,4, Steven J Shoptaw1,5, Edythe D London6,7,8

1Department of Psychiatry and Mental Health, University of Cape Town, Neuroscience Institute, South Africa
2Department of Paediatrics and Child Health, University of Cape Town, Neuroscience Institute, South Africa
3South African Medical Research Council Unit on Risk & Resilience in Mental Disorders
4Department of Psychiatry and Neuroscience Institute, University of Cape Town, Cape Town, South Africa
5Department of Family Medicine, University of California at Los Angeles, Los Angeles, California, United States of America
6Department of Psychiatry and Biobehavioral Sciences, University of California at Los Angeles, Los Angeles, California, United States of America
7Department of Molecular and Medical Pharmacology, University of California at Los Angeles, Los Angeles, California, United States of America
8The Brain Research Institute, University of California at Los Angeles, Los Angeles, California, United States of America

Abstract

Objectives: Contingency management is a promising intervention for Methamphetamine Use Disorder (MUD). Impaired executive function may decrease adherence to such treatment, but there are few data on whether impairment in executive function predicts treatment outcomes. We therefore evaluated whether baseline performance on tests of executive function predicted treatment response in a trial of contingency management for MUD.

Methods: Thirty participants with MUD and 23 healthy controls performed the Connors Continuous Performance Task (CPT) and the Trail Making Task. MUD participants then entered an 8-week contingency management trial. Participants were categorized as responders (n=17; no methamphetamine-positive urine tests) or non-responders (n=13; >1 positive test). The Kruskal-
Wallis test was used to compare scores in participants with MUD and healthy controls, and in responders versus non-responders.

**Results:** Participants with MUD performed worse than controls on the CPT (d-prime) \((p=0.012)\); non-responders performed worse than responders \((p = 0.034)\). Performance of MUD participants did not differ significantly from controls on the Trail Making Task B (time to completion), but variation was high with non-responders performing worse than responders \((p=0.013)\).

**Conclusion:** These findings suggest that tests of executive function at baseline may be useful in predicting treatment response in MUD. Future work in larger samples may ultimately allow a more personalized treatment approach to methamphetamine use disorder.

**Keywords**

Executive function; Methamphetamine use disorder; Contingency management

---

**INTRODUCTION**

Contingency management has shown promise in treating Methamphetamine Use Disorder (MUD) [1]. This treatment approach relies on the use of rewards for drug abstinence [2]. Notably, individuals with MUD exhibit compromised executive dysfunction [3-5], and such cognitive deficits have been linked to lower adherence to behavioural treatment [6]. In work by this group, scores on a test of decision-making, balancing rewards and penalties, participants who had a worse response to treatment also performed more poorly than those that did respond to treatment and healthy controls at baseline [7].

There are, however, few data on whether impairment in executive function predicts treatment response in MUD. Identifying predictors of treatment outcome can facilitate the development of personalized approaches to management. Yet the availability of individualized treatment for stimulant use disorders remains aspirational.

We recently demonstrated the efficacy of contingency management for MUD in a South African sample [2]. Here we employ these data to test the hypothesis that impairment in executive function at baseline predicts subsequent response to contingency management.

**METHODS**

**Study Design**

Data are from a pilot study evaluating an 8-week, escalating schedule of contingency management for treatment of MUD in a South African context. Full details of this trial are presented elsewhere [2]. The study was conducted according to the Principles of the Declaration of Helsinki; all research was overseen by the Health Science Human Research Ethics Committee of the University of Cape Town and the UCLA Institutional Review Board, and all participants provided written informed consent. Before participants entered the trial they completed the Wechsler Abbreviated Scale of Intelligence (WASI) [8] and the Montreal Cognitive Assessment (MoCA) [9] to evaluate overall cognitive function, as well as the Revised Hamilton Rating Scale for Depression (RHRSD) [10], the Addiction Severity Index (ASI) [11] and the Childhood Trauma Questionnaire [12]. Two laboratory tests of
executive function were administered: the Connors Continuous Performance Task (CPT) [13] and the Trail-Making Task-B (TMT-B) [14].

**Research Participants**

Potential participants who were not receiving treatment were recruited through advertisements, and others who were referred from treatment centres were receiving motivational interviewing as therapy. They were screened using the Structured Clinical Interview for DSM-5 (SCID-5) to identify those who met criteria for MUD. No other psychiatric comorbidities were allowed, except for Tobacco Use Disorder and Antisocial Personality Disorder, which are common co-morbidities associated with MUD [15-17]. Controls were matched using frequency matching to the MUD group on sex, race, age (age groups were as follows 18-22, 23-27, 28-32, 33-37, 38-42, 43-45), education (number of years of education were as follows 4-7, 8-10, 10-12, 13+), IQ (IQ ranges were as follows 60-69, 70-79, 80-89, 90-99, 100-109, 110-119, 120-129), Fagerström score, number of cigarettes smoked daily (between 0-4, 5-10, 11-15, 16-20 and 20+) and household income (SES score 1 to 5).

**Cognitive Tests**

Both controls and MUD participants completed the cognitive tests in a quiet room with few or no distractions. Participants in the MUD group were tested before they entered the treatment trial, and control participants completed a baseline test session. The CPT was presented on a Dell Intel core i3 laptop, Vostro 2520 with a 15-inch screen using E-Prime software version 2.0, and the TMT-B was administered using paper and pencil.

The CPT and TMT-B were selected to evaluate different aspects of executive function. The CPT measures sustained attention, inattentiveness, impulsivity, and vigilance [18]. The primary outcome measure for this test was d-prime, which indicates the ability to discriminate targets from non-targets in response to cues. The TMT provides information on visual searching, scanning, speed of processing, and mental flexibility. Part B of the TMT test was used for this, and speed to completion was the primary outcome measure.

**Data Analysis**

For each outcome measure (d-prime and time to completion), we determined whether the data were normally distributed, and then tested for homoscedasticity [19]. Since the data did not meet assumptions of normality and homoscedasticity, the non-parametric Kruskal Wallis Test was used to compare groups, and alpha was set at p<0.05. The Benjamini Hochberg adjustment was used to control for multiple comparisons with a false discovery rate of 0.05. In addition to comparing outcome measures in treatment responders vs non-responders, we also assessed whether MUD participants vs healthy controls was associated with differences in executive function.

**RESULTS**

Sociodemographic and clinical variables of research participants were tabulated (Table 1). The groups differed in education with controls having completed more years than the MUD
group (p=0.009). Seven of the 30 participants in the MUD group but none of the controls met the diagnostic criteria for Antisocial Personality Disorder (p=0.001). The MUD group also was significantly more depressed than the controls (p=0.001).

With respect to the cognitive tasks (Table 2), responders to treatment had significantly greater d-prime than non-responders on the CPT (p=0.034), and also exhibited a significantly shorter time to completion on the TMT-B than non-responders (p=0.013). MUD participants had significantly lower d-prime than controls (p=0.012 on the CPT, but the groups did not differ in performance on the TMT-B p>0.05).

DISCUSSION

Our findings confirm the hypothesis that treatment non-responders had worse executive function than responders, with responders having greater d-prime and having shorter time to completion on the CPT. This is a novel finding, and suggests that stronger attentional resources may enable patients to adhere to behavioural interventions over the short term. Such resources may correspond with capacity to engage escalating reinforcement procedures during contingency management to produce methamphetamine abstinence.

A comparison group of healthy controls, similar to the MUD group along most demographic and cognitive variables, completed more years of education than participants with MUD but scored similarly along a global measure of intellectual functioning that has been used for this purpose in South Africa [20]. This likely indicates that participants with MUD had early histories of social and educational disadvantage compared to controls. Other group differences highlighted factors common to persons diagnosed with MUD, including comorbid Antisocial Personality Disorder (Conduct Disorder as a child/adolescent) and elevated depression symptoms. Neither of these factors that distinguished MUD participants from controls, however, interfered with treatment outcomes for MUD in U.S. [21,22].

A number of limitations deserve emphasis. First, the sample size is small. There is the potential for false negative findings, and we were unable to explore the impact of confounders such as comorbid depression on task performance. Second the scope of testing was limited. Aspects of executive function that should be explored in further work in MUD patients include suppressing an automated response as assessed by tasks such as the Hayling Sentence Completion [23], and discovery of rules, as measured using tasks such as the Brixton Spatial Anticipation Test [24].

Despite these limitations, we were able to confirm our hypothesis of an association between impaired executive function and treatment outcome in a trial of contingency management. Inclusion of executive function tests, such as the CPT, may be a useful part of an assessment of individuals with MUD prior to CM. It is possible that individuals with poor performance would benefit from a combination therapy including cognitive training [25] or a treatment augmentation using medications that can help reduce methamphetamine use during treatment [26-28].
CONCLUSION

The finding that responders to treatment performed better on tasks of executive function suggests that tests of this neurocognitive domain may be useful in predicting treatment response in MUD. Future work in larger samples may ultimately allow a more personalized treatment approach to methamphetamine use disorder.

ACKNOWLEDGEMENTS

SJS, DJS and EDL wrote the initial protocol for this study. LJvN drafted the current manuscript and MTL aided in statistical analysis. All authors made further edits in order to finalise the manuscript.

FUNDING

This work was supported by the grants from the US National Institutes of Health: R21DA04049 and 1MH P30 058107.

REFERENCES

1. Shoptaw S, Klausner JD, Reback CJ, Tierney S, Stansell J, Hare CB, et al. A public health response to the methamphetamine epidemic: the implementation of contingency management to treat methamphetamine dependence. BMC public health. 2006; 6:1–5. [PubMed: 16390547]
2. Okafor CN, Stein DJ, Dannatt L, Ipser J, van Nunen LJ, Lake MT, et al. Contingency management treatment for methamphetamine use disorder in South Africa. Drug and Alcohol Review. 2019.
3. Cattie JE, Woods SP, Iudicello JE, Posada C, Grant I, TMARC Group. Elevated neurobehavioral symptoms are associated with everyday functioning problems in chronic methamphetamine users. The Journal of neuropsychiatry and clinical neurosciences. 2012; 24(3):331–339. [PubMed: 23037647]
4. Dean AC, Groman SM, Morales AM, London ED. An evaluation of the evidence that methamphetamine abuse causes cognitive decline in humans. Neuropsychopharmacology. 2013; 38(2):259. [PubMed: 22948978]
5. van der Plas EA, Crone EA, van den Wildenberg WP, Tranel D, Bechara A. Executive control deficits in substance-dependent individuals: a comparison of alcohol, cocaine, and methamphetamine and of men and women. Journal of clinical and experimental neuropsychology. 2009; 31(6):706–719. [PubMed: 19037812]
6. Kiluk BD, Buck MB, Devore KA, Babuscio TA, Nich C, Carroll KM. Performance-based contingency management in cognitive remediation training: A pilot study. Journal of substance abuse treatment. 2017; 72:80–88. [PubMed: 27590364]
7. Lake MT, Shoptaw S, Ipser JC, Takada S, van Nunen LJ, Lipinska G, et al. Decision-Making by Patients With Methamphetamine Use Disorder Receiving Contingency Management Treatment: Magnitude and Frequency Effects. Frontiers in Psychiatry. 2020; 11:22. [PubMed: 32180733]
8. Wechsler D Wechsler Abbreviated Scale of Intelligence™ (WASI™). 2017.
9. Gierus J, Mosiolek A, Koweszko T, Wnukiewicz P, Kozyra O, Szulc A. The Montreal Cognitive Assessment as a preliminary assessment tool in general psychiatry: Validity of MoCA in psychiatric patients. General hospital psychiatry. 2015; 37(5):476–480. [PubMed: 26054843]
10. Warren WL. Revised Hamilton Rating Scale for Depression (RHRSD): Western Psychological Services. 1998.
11. McLellan AT, Cacciola JC, Alterman AI, Rikoon SH, Carise D. The Addiction Severity Index at 25: origins, contributions and transitions. The American journal on addictions. 2006; 15(2):113–124.
12. Bernstein DP, Stein IA, Newcomb MD, Walker E, Pogge D, Ahluvalia T, et al. Development and validation of a brief screening version of the Childhood Trauma Questionnaire. Child abuse & neglect. 2003; 27(2):169–190. [PubMed: 12615092]
13. Riccio CA, Reynolds CR, Lowe P, Moore JJ. The continuous performance test: a window on the neural substrates for attention? Archives of clinical neuropsychology: the official journal of the National Academy of Neuropsychologists. 2002; 17(3):235–272. [PubMed: 14589726]

14. Sanchez-Cubillo I, Perianez JA, Adrover-Roig D, Rodriguez-Sanchez JM, Rios-Lago M, Tirapu JE, et al. Construct validity of the Trail Making Test: role of task-switching, working memory, inhibition/interference control, and visuomotor abilities. Journal of the International Neuropsychological Society. JINS. 2009; 15(3):438–450. [PubMed: 19402930]

15. Fletcher JB, Reback CJ. Antisocial personality disorder predicts methamphetamine treatment outcomes in homeless, substance-dependent men who have sex with men. Journal of substance abuse treatment. 2013; 45(3):266–272. [PubMed: 23579078]

16. Weinberger AH, Sofuoglu M. The impact of cigarette smoking on stimulant addiction. The American Journal of Drug and Alcohol Abuse. 2009; 35(1):12–17. [PubMed: 19152200]

17. Morales AM, Kohno M, Robertson CL, Dean AC, Mandelkern MA, London ED. Gray-matter volume, midbrain dopamine D2/D3 receptors and drug craving in methamphetamine users. Molecular psychiatry. 2015; 20(6):764–771. [PubMed: 25896164]

18. Conners CK, Staff M, Connelly V, Campbell S, MacLean M, Barnes J. Conners’ continuous performance Test II (CPT II v. 5). Multi-Health Syst Inc. 2000; 29:175–196.

19. Koenker R, Bassett G Jr. Robust tests for heteroscedasticity based on regression quantiles. Econometrica: Journal of the Econometric Society. 1982;43–61.

20. Ellison GT. Health, wealth and IQ in sub-Saharan Africa: challenges facing the 'Savanna Principle' as an explanation for global inequalities in health. (1359-107X (Print)).

21. Gunter TD, Black DW, Zwick J, Arndt S. Drug and alcohol treatment services effective for methamphetamine abuse. Annals of clinical psychiatry: official journal of the American Academy of Clinical Psychiatrists. 2004; 16(4):195–200. [PubMed: 15702567]

22. Lisa P, Felicia K, Laura H, Daniela K, Marlies R, Stefanie N, et al. Associations between methamphetamine use, psychiatric comorbidities and treatment outcome in two inpatient rehabilitation centers. Psychiatry research. 2019; 280:112505. [PubMed: 31382181]

23. Burgess PW, Shallice T. Response suppression, initiation and strategy use following frontal lobe lesions. Neuropsychologia 1996; 34(4):263–272. [PubMed: 8657357]

24. Burgess PW, Shallice T. Bizarre responses, rule detection and frontal lobe lesions. Cortex. 1996; 32(2):241–259. [PubMed: 880613]

25. Hart CL, Marvin CB, Silver R, Smith EE. Is cognitive functioning impaired in methamphetamine users? A critical review. Neuropsychopharmacology. 2012; 37(3):586. [PubMed: 22089317]

26. Trivedi MH, Walker R, Ling W, Dela Cruz A, Sharma G, Carmody T, et al. Bupropion and Naltrexone in Methamphetamine Use Disorder. N Engl J Med. 2021; 384(2):140–153. [PubMed: 33497547]

27. Colfax GN, Santos GM, Das M, Santos DM, Matheson T, Gasper J, et al. Mirtazapine to reduce methamphetamine use: A randomized controlled trial. Archives of General Psychiatry. 2011; 68(11):1168–1175. [PubMed: 22065532]

28. Coffin PO, Santos GM, Herr J, Vittinghoff E, Walker JE, Matheson T, et al. Effects of Mirtazapine for Methamphetamine Use Disorder Among Cisgender Men and Transgender Women Who Have Sex With Men: A Placebo-Controlled Randomized Clinical Trial. JAMA Psychiatry. 2020; 77(3):246–255. [PubMed: 31825466]
### Table 1:

Demographics.

|                  | Means ± Std.dev | Means ± Std.dev |
|------------------|-----------------|-----------------|
|                  | Healthy Controls (n = 23) | MUD group (n = 30) | Wilcoxon Rank Sum |
| **Age**          | 35.2 ± 7.0       | 34.3 ± 6.2       | 33.8 ± 6.7         | 35.1 ± 5.6         | p = 0.577 | p = 0.706 |
| **Race**         | 21 MRA, 2 African descent | 28 MRA, 2 African descent | - | 15 MRA, 2 African descent | 13 MRA | - |
| **Education**    | 12.5 ± 1.4       | 10.9 ± 2.9       | 11.8 ± 2.9         | 9.6 ± 2.3         | p = 0.009** | p = 0.055+ |
| **WASI IQ**      | 83.5 ± 15.8      | 84.7 ± 15.7      | 86.2 ± 18.4        | 82.9 ± 11.8       | p = 0.781 | p = 0.706 |
| **RHRSD**        | 5.4 ± 6.1        | 26.6 ± 23.2      | 28.7 ± 24.2        | 23.8 ± 22.5       | p = 0.001**** | p = 0.722 |
| **Household Income (monthly)** | R 20108.70 ± R17113.89 | R16250.00 ± R15725.97 | p = 0.206 | R9117.65 ± R11522.44 | R25576.92 ± R15947.63 | p = 0.009** |
| **Employment at time of trial** | 58% | 9% | - | 16% | 0% | - |
| **Cigarettes smoked daily** | 6.9 ± 6.7 | 8.3 ± 7.6 | p = 0.568 | 6.8 ± 6.0 | 10.2 ± 9.1 | p = 0.486 |
| **ASPD** | 0 | 7 | p = 0.001** | 3 | 4 | - |
| **ASI total drug score** | 0.3 ± 0.1 | 0.3 ± 0.1 | p = 0.690 | 0.3 ± 0.1 | 0.3 ± 0.1 | p = 0.690 |
| **Grains per day** | 0.9 ± 0.5 | 1 ± 0.6 | - | - | 0.9 ± 0.5 | 1.1 ± 0.7 | p = 0.372 |
| **Years of misuse** | 10.0 ± 4.4 | 11.3 ± 4.2 | - | - | 10.0 ± 4.4 | 12.9 ± 3.5 | p = 0.119 |
| **Amount spent monthly** | R2394.62 ± R1524.73 | R1370.83 ± R1377.00 | R1399.71 ± R1112.38 | - | R1370.83 ± R1377.00 | R2394.62 ± R1524.73 | p = 0.062+ |
| **Age initiated** | 22.5 ± 6.3 | 22.5 ± 6.3 | - | - | 22.4 ± 6.3 | 22.5 ± 6.5 | p = 0.950 |
| **Number of urine samples drug negative before scan** | 4.9 ± 3.3 | 3.8 ± 2.9 | - | - | 4.9 ± 3.3 | 2.3 ± 1.0 | p = 0.005** |

Demographics data presented for between MUD and control groups, and within MUD group (ASI = Addiction Severity Index, ASPD = antisocial personality disorder, CTQ - Childhood trauma questionnaire, MRA = Mixed race ancestry, RHRSH = Revised Hamilton Rating Scale for Depression, stars (*) flag levels of significance with one star denoting a p value below 0.05, two if the p value is less than 0.01 and three for less that p = 0.001)
Table 2:

Performance on Executive Function Tests.

| Connors Continuous Performance Task D’prime | Median | Q1 | Q3 | IQR   | Kruskal Wallis | Benjamini Hochberg |
|---------------------------------------------|--------|----|----|-------|----------------|-------------------|
| Healthy control                             | 3.196  | 3.015 | 3.319 | 0.475 | p = 0.012*      | p = 0.012*       |
| Methamphetamine Use Disorder                | 2.983  | 2.711 | 3.186 | 0.304 |                |                   |
| Responders to treatment                     | 3.013  | 2.823 | 3.21 | 0.387 | p = 0.034*      | p = 0.061+       |
| Non-responders to treatment                 | 2.937  | 2.69 | 3.052 | 0.362 |                |                   |

| Trail Making Task B                         | Median | Q1 | Q3 | IQR   | Kruskal Wallis | Benjamini Hochberg |
|---------------------------------------------|--------|----|----|-------|----------------|-------------------|
| Time to Completion                          |        |    |    |       |                |                   |
| MA Group                                    | 152.80 | 113.68 | 231.00 | 117.32 | p = 0.554       | p = 0.554        |
| Healthy controls                            | 116.50 | 89.355 | 214.7 | 125.345 |                |                   |
| Responders to treatment                     | 119.60 | 92.93 | 141.875 | 48.945 | p = 0.013*      | p = 0.039*       |
| Non-responders to treatment                 | 198.21 | 136.73 | 233.93 | 97.21 |                |                   |

Data are presented for 23 healthy control participants and 30 participants with Methamphetamine Use Disorder (17 responders to contingency management treatment, 13 non-responders). Data marked with an asterisk reached the criterion for statistical significance, the Benjamini Hochberg multiple comparisons correction was conducted for two tests.